AIA Group Ltd Has $12.31 Million Stock Holdings in Pfizer Inc. $PFE

AIA Group Ltd boosted its stake in Pfizer Inc. (NYSE:PFE) by 137.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 483,248 shares of the biopharmaceutical company’s stock after buying an additional 279,705 shares during the quarter. AIA Group Ltd’s holdings in Pfizer were worth $12,313,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer during the third quarter worth $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer during the second quarter valued at $30,000. Darwin Wealth Management LLC purchased a new position in Pfizer in the second quarter valued at about $32,000. Evelyn Partners Asset Management Ltd acquired a new position in Pfizer in the 2nd quarter worth about $33,000. Finally, True Wealth Design LLC raised its stake in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Royal Bank Of Canada initiated coverage on Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target for the company. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. UBS Group began coverage on shares of Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price for the company. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.14.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase‑2 win for atirmociclib: Pfizer reported positive topline results from the randomized FOURLIGHT‑1 study showing its next‑generation CDK4 inhibitor plus fulvestrant met the primary endpoint and reduced risk of progression or death (~40%). The result strengthens Pfizer’s oncology pipeline and positions atirmociclib as a potential successor/competitive option to existing CDK4/6 therapies. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Analyst upgrade/price‑target raise: HSBC raised its price target on PFE to $32 and maintained a Buy rating, giving investors an incremental valuation tailwind and signaling analyst confidence in Pfizer’s medium‑term outlook. HSBC Raises Price Target on Pfizer
• Neutral Sentiment: Early liver program progress: Pfizer advanced a Phase‑1 study of PF‑07328948 (liver indication), an early readout that modestly adds breadth to the pipeline but is unlikely to drive material near‑term revenue given its very early stage. Pfizer Advances Early PF-07328948 Liver Study
• Neutral Sentiment: Market/commentary noise: Media/analyst chatter (including TV commentary and bullish opinion pieces) is drawing attention to Pfizer’s broad pipeline and long‑term potential, but these are sentiment drivers rather than new clinical or commercial facts. Expect short‑term volatility around headlines. Jim Cramer Notes Pfizer Has “Got a Lot of Stuff in the Pipeline”
• Negative Sentiment: Study termination in melanoma: Pfizer ended a Phase‑1 study of PF‑08046031 in early‑stage melanoma, trimming one oncology program. While not expected to be material to top‑line forecasts, it marginally reduces pipeline optionality and is a near‑term negative datapoint for investors focused on oncology depth. Pfizer Ends Early-Stage Melanoma Study

Pfizer Stock Down 0.5%

PFE opened at $27.33 on Thursday. The business has a 50 day moving average of $26.61 and a 200-day moving average of $25.57. The stock has a market capitalization of $155.38 billion, a price-to-earnings ratio of 20.09 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the company posted $0.63 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.